Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …

The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …

Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

Lung cancer continues to be a major health problem and the most common cancer-related
mortality worldwide with about 80%–85% patients suffering from nonsmall cell lung cancer …

Lung cancer remains the leading cause of cancer-related death. Non-small cell lung cancer
(NSCLC) represents 85% of all lung cancer cases and it is classified into three major …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly
improved the survival of patients with advanced non-small cell lung cancer (NSCLC) …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …